Despite and because of all the challenges lined up between bench-top and commercialization, it is critical to take a market-driven approach when picking a synthetic biology product.
Here are three must-have sections for when you’re compiling your empirical evidence:
We’re wrapping up 2021 with anticipated ~50B record high investments in climate tech. Despite the capital rush, we stay disciplined to our market-driven approach, looking for deployable solutions with clear economic incentives.
Currently, the only treatment for hydrocephalus is to place a shunt in order to drain the excess fluid. Patients rely on these shunts for the rest of their lives but shunts are bound to fail. The failure rate is as high as 50% just 18 months after the placement.
Climate change plays a central role in diminishing resources and agricultural outputs. In parallel, the demand for animal-based foods is undeniably on the rise. The question, therefore, is how do we increase the limited supplies of animal-based proteins or their equivalents?
Remote Patient Monitoring (RPM), the monitoring of patients outside a traditional clinical setting, has received an influx of capital over the past few years. The space saw a growth spike in 2020, courtesy of the pandemic.
Is this a transient hype, or did the pandemic catalyze a shift to remote healthcare services for good? Here, we’ll take a closer look at some primary driving forces for RPM adoption, and point out what we believe to be the most exciting opportunities.
As a deep tech fund, we come across a fair share of platform-tech startups. The promise of supposedly expandable market opportunities is auspicious for growth and return. Though oftentimes, many fall into execution traps, especially earlier on in the life cycle.
While some missteps may be reversible, others exhaust already limited resources and lead to a point of no return.
The underlying macrotrends, current solutions and investment opportunities Creative Ventures recently led an investment into VenoStent, an advanced-material technology company working on eliminating the 50%+ failure rate in vascular-access surgery required to initiate hemodialysis. Here we unravel the underlying macrotrends driving the development of solutions and investment opportunities in this sector. The kidneys are amongContinue reading “Kidney Disease: A Silent (and Costly) Killer”